Dr Julia M.W. Gee

Dr Julia M.W. Gee - PhD

If you get this message then javascript is not enabled within your browser.

Peer reviewed articles

Over 100, including the following since 2001:

Morgan L, Gee J, Pumford S, Farrow L, Finlay P, Robertson J, Ellis I, Kawakatsu H, Nicholson R, Hiscox S. Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol Ther. 2009 Aug;8(16):1550-8.

Blamey RW, Hornmark-Stenstam B, Ball G, Blichert-Toft M, Cataliotti L, Fourquet A, Gee J, Holli K, Jakesz R, Kerin M, Mansel R, Nicholson R, Pienkowski T, Pinder S, Sundquist M, van de Vijver M, Ellis I. ONCOPOOL - A European database for 16,944 cases of breast cancer. Eur J Cancer. 2010 Jan;46(1):56-71.

Gutteridge E, Agrawal A, Nicholson R, Cheung KL, Robertson J, Gee J. The effects of gefitinib in tamoxifen resistant and hormone insensitive breast cancer: A phase II study. Int J Cancer. 2010 Apr 15;126(8):1806-16.

Thomas NB, Hutcheson IR, Campbell L, Gee J, Taylor KM, Nicholson RI, Gumbleton M. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGFR mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91.

Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Douglas Macmillan R, Nicholson RI, Ellis IO, Gee JM. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat. 2010 Jan;119(2):283-93.

Jasani, B., Gee, J., Hutcheson, I., Clarkson, R.W., Bartlett, J., and Barrett-Lee, P. (2009). Resistance to HER2-directed trastuzumab therapy in breast cancer. Advances in Breast Cancer 6, 11-18.

Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Research 2008 Dec 15;68(24):10238-46.

Borley AC, Hiscox S, Gee J, Smith C, Shaw V, Barrett-Lee P, Nicholson RI. Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells. Breast Cancer Res. 2008 Dec 4;10(6):R103.

Gee J, Eloranta J, Ibbitt J, Robertson J, Ellis I, Williams T, Nicholson R, Hurst H. Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. J Pathol. 2008 Aug 26;217(1):32-41.

Davison Z, Dutkowski C, Gee JM, Nicholson RI, Heard CM. In vitro effects on MCF-7 breast cancer cells of signal transduction inhibitor/tamoxifen/ eicosapentaenoic acid combinations and their simultaneous delivery across skin. Pharm Res. 2008 Nov;25(11):2516-25.

Knowlden JM, Jones HE, Barrow D, Gee JM, Nicholson RI, Hutcheson IR. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Res Treat. 2008 Sep;111(1):79-91.

Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer. 2008 Jul;44(11):1541-51.

Thompson A, Brennan K, Cox A, Gee J, Harcourt D, Harris A, Harvie M, Holen I, Howell A, Nicholson R, Steel M, Streuli C. Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res. 2008;10(2):R26.

Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, Robertson JF, Blamey R, Gee J, Nicholson RI, Lee AH, Ellis IO. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer. 2008 Jan;44(1):73-83.

Assender JW, Gee JM, Lewis I, Ellis IO, Robertson JF, Nicholson RI. (2007) Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol. 60:1216-21.

Greco, F., Vicent, M.J., Gee, S., Jones, A.T., Gee, J., Nicholson, R.I. & Duncan, R. (2007). Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells. J Control Release, 117, 28-39.

Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson R (2007). Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res.8; 9(4):R50.

Nicholson RI, Hutcheson IR, Jones HE, Hiscox SE, Giles M, Taylor KM, Gee JM. (2007). Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Rev Endocr Metab Disord. 8:241-53.

Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO (2007). Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 25:4772-8.

Robertson JF, Semiglazov V, Nemsadze G, Dzagnidze G, Janjalia M, Nicholson RI, Gee JM, Armstrong J; Study 41 Investigators (2007). Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer. Eur J Cancer. 43, 64-70.

Gee JM, Shaw VE, Hiscox SE, McClelland RA, Rushmere NK, Nicholson RI. (2006) Deciphering anti‑hormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocr Relat Cancer. 13,:S77-88.

Hutcheson IR, Knowlden JM, Jones HE, Burmi RS, McClelland RA, Barrow D,
Gee JM, Nicholson RI. (2006) Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocr Relat Cancer. 13::S89-97.

Jasani, B., Douglas-Jones, A., Rhodes, A., Wozniak, S., Barrett-Lee, P.J.,Gee, J. & Nicholson, R. (2006). Measurement of oestrogen receptor status by immunocytochemistry in paraffin wax sections. Methods Mol Med, 120, 127-46.

Jones HE, Gee JM, Hutcheson IR, Knowlden JM, Barrow D, Nicholson RI. (2006) Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer. 13,:S45-51.

Jones, H.E., Gee, J.M., Barrow, D., Tonge, D., Holloway, B. & Nicholson, R.I. (2006). Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. Br J Cancer, 95, 172-80.

Sarwar, N., Kim, J.-S., Jiang, J., Peston, D., Sinnett, H.D., Madden, P., Gee, J.M., Nicholson, R.I., Lykkesfeldt, A.E., Shousha, S., Coombes, R.C. & Ali, S. (2006). Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr Relat Cancer. 13, 851-61.

Agrawal, A., Gutteridge, E., Gee, J.M., Nicholson, R.I. & Robertson, J.F. (2005). Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer, 12 Suppl 1, S135-44.

Britton, D.J., Hutcheson, I.R., Knowlden, J.M., Barrow, D., Giles, M., McClelland, R.A., Gee, J.M. & Nicholson, R.I. (2005). Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat, 1-16

Gee, J.M., Howell, A., Gullick, W.J., Benz, C.C., Sutherland, R.L., Santen, R.J., Martin, L.A., Ciardiello, F., Miller, W.R., Dowsett, M., Barrett-Lee, P., Robertson, J.F., Johnston, S.R., Jones, H.E., Wakeling, A.E., Duncan, R. & Nicholson, R.I. (2005). Consensus statement. Endocr Relat Cancer, 12 Suppl 1, S1-7.

Gee, J.M. & Hutcheson, I.R. (2005). Understanding endocrine resistance: the critical need for sequential samples from clinical breast cancer and novel in vitro models. Breast Cancer Res, 7, 187-9.

Gee, J.M., Robertson, J.F., Gutteridge, E., Ellis, I.O., Pinder, S.E., Rubini, M. & Nicholson, R.I. (2005). Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer, 12 Suppl 1, S99-S111.

Hiscox, S., Morgan, L., Green, T.P., Barrow, D., Gee, J. & Nicholson, R.I. (2005). Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat, 1-12.

Jones, H.E., Gee, J.M., Taylor, K.M., Barrow, D., Williams, H.D., Rubini, M. & Nicholson, R.I. (2005). Development of strategies for the use of anti-growth factor treatments. Endocr Relat Cancer, 12 Suppl 1, S173-82.

Knowlden, J.M., Hutcheson, I.R., Barrow, D., Gee, J.M. & Nicholson, R.I. (2005). IGF-IR signalling in tamoxifen-resistant breast cancer: a supporting role to the EGFR. Endocrinology. 46:4609-18.

Nicholson, R.I., Hutcheson, I.R., Britton, D., Knowlden, J.M., Jones, H.E., Harper, M.E., Hiscox, S.E., Barrow, D. & Gee, J.M. (2005). Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. J Steroid Biochem Mol Biol, 93, 257-62.

Nicholson, R.I., Hutcheson, I.R., Hiscox, S.E., Knowlden, J.M., Giles, M., Barrow, D. & Gee, J.M. (2005). Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer, 12 Suppl 1, S29-36.

Staka, C.M., Nicholson, R.I. & Gee, J.M. (2005). Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. Endocr Relat Cancer, 12 Suppl 1, S85-97.

Jones, H.E., Goddard, L., Gee, J.M., Hiscox, S., Rubini, M., Barrow, D., Knowlden, J.M., Williams, S., Wakeling, A.E. & Nicholson, R.I. (2004). Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer, 11, 793-814.

Jones, H.E., Nicholson, R.I., Hutcheson, I.R., Knowlden, J.M., Harper, M.E., Jordan, N., Hiscox, S.E., Barrow, D. & Gee, J.M.W. (2004). Endocrine resistance in breast cancer:therapeutic intervention using signal transduction inhibitors. Advances in Breast Cancer, 1, 3.

Jordan, N.J., Gee, J.M., Barrow, D., Wakeling, A.E. & Nicholson, R.I. (2004). Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat, 87, 167-80.

Nicholson, R.I., Hutcheson, I.R., Knowlden, J.M., Jones, H.E., Harper, M.E., Jordan, N., Hiscox, S.E., Barrow, D. & Gee, J.M. (2004). Nonendocrine pathways and endocrine resistance: observations with anti-oestrogens and signal transduction inhibitors in combination. Clin Cancer Res, 10, 346S-54S.

Nicholson, R.I., Staka, C., Boyns, F., Hutcheson, I.R. & Gee, J.M. (2004). Growth factor-driven mechanisms associated with resistance to oestrogen deprivation in breast cancer: new opportunities for therapy. Endocr Relat Cancer, 11, 623-41.

Rushmere, N.K., Knowlden, J.M., Gee, J.M., Harper, M.E., Robertson, J.F., Morgan, B.P. & Nicholson, R.I. (2004). Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. Int J Cancer, 108, 930-6

Gee, J.M., Harper, M.E., Hutcheson, I.R., Madden, T.A., Barrow, D., Knowlden, J.M., McClelland, R.A., Jordan, N., Wakeling, A.E. & Nicholson, R.I. (2003). The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves anti‑hormone response and prevents development of resistance in breast cancer in vitro. Endocrinology, 144, 5105-17.

Hutcheson, I.R., Knowlden, J.M., Madden, T.A., Barrow, D., Gee, J.M., Wakeling, A.E. & Nicholson, R.I. (2003). Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat, 81, 81-93.

Knowlden, J.M., Hutcheson, I.R., Jones, H.E., Madden, T., Gee, J.M., Harper, M.E., Barrow, D., Wakeling, A.E. & Nicholson, R.I. (2003). Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology, 144, 1032-44.

Nicholson, R.I., Gee, J.M., Knowlden, J., McClelland, R., Madden, T.A., Barrow, D. & Hutcheson, I. (2003). The biology of anti‑hormone failure in breast cancer. Breast Cancer Res Treat, 80 Suppl 1, S29-34; discussion S35.

Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J.M., Herbst, R., LoRusso, P., Rischin, D., Sauleda, S., Gee, J., Nicholson, R.I. & Baselga, J. (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol, 20, 110-24.

Chan, K.C., Knox, W.F., Gee, J.M., Morris, J., Nicholson, R.I., Potten, C.S. & Bundred, N.J. (2002). Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res, 62, 122-8.

Nicholson, R.I., Hutcheson, I.R., Harper, M.E., Knowlden, J.M., Barrow, D., McClelland, R.A., Jones, H.E., Wakeling, A.E. & Gee, J.M.W. (2002). Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen-receptor-positive breast cancer. Ann N Y Acad Sci, 963, 104-15.

Gee, J.M., Robertson, J.F., Ellis, I.O. & Nicholson, R.I. (2001). Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer, 95, 247-54.

Glynne-Jones, E., Harper, M.E., Seery, L.T., James, R., Anglin, I., Morgan, H.E., Taylor, K.M., Gee, J.M. & Nicholson, R.I. (2001). TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence. Int J Cancer, 94, 178-84.

Kenny, F, Gee, J, Nicholson, R., Ellis, I.O., Morris, T.M., Watson, S.A., Bryce, R.P. & Robertson, J.F. (2001). Effect of dietary GLA+/-tamoxifen on growth, ER expression & fatty acid profile of ER+ human breast cancer xenografts. Int J Can. 92, 342-7.

Kenny, F.S., Willsher, P.C., Gee, J.M., Nicholson, R., Pinder, S.E., Ellis, I.O. & Robertson, J.F. (2001). Change in expression of ER, bcl-2 & MIB1 on primary tamoxifen and relation to response in ER positive breast cancer. Breast Cancer Res Treat, 65, 135-44.

McClelland, R.A., Barrow, D., Madden, T.A., Dutkowski, C.M., Pamment, J., Knowlden, J.M., Gee, J.M. & Nicholson, R.I. (2001). Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antioestrogen ICI 182,780 (Faslodex). Endocrinology, 142, 2776-88.

Nicholson, R.I., Gee, J.M. & Harper, M.E. (2001). EGFR and cancer prognosis. Eur J Cancer, 37 Suppl 4, S9-15.

Nicholson, R.I., Hutcheson, I.R., Harper, M.E., Knowlden, J.M., Barrow, D., McClelland, R.A., Jones, H.E., Wakeling, A.E. & Gee, J.M. (2001). Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer, 8, 175-82.

Robertson, J.F., Nicholson, R.I., Bundred, N.J., Anderson, E., Rayter, Z., Dowsett, M., Fox, J.N., Gee, J.M., Webster, A., Wakeling, A.E., Morris, C. & Dixon, M. (2001). Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5- pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res, 61, 6739-46.

Wakeling, A.E., Nicholson, R.I. & Gee, J.M. (2001). Prospects for combining hormonal and nonhormonal growth factor inhibition. Clin Cancer Res, 7, 4350s-4355s; discussion 4411s-4412s.

Books and book chapters since 2001

Edited book:

Eds: Hiscox S, Gee J and Nicholson RI. “Therapeutic resistance to anti-hormonal drugs in breast cancer: new molecular aspects and their potential as targets”. Feb. 2009, Springer Publishing, London.

Gee JMW, Stone A, McClelland RA, Hiscox SE, Hutcheson IR, Jordon NJ, Fiegl HM, Widschwendter M, Shaw VE, Barrow D & Nicholson RI. The dark side of antihormonal action in breast cancer. In: Therapeutic resistance to anti-hormonal drugs in breast cancer: new molecular aspects and their potential as targets. Eds: Hiscox S, Gee J and Nicholson RI 2009. Springer Publishing, London, pp63-84.

Nicholson RI, Hutcheson IR, Hiscox S, Taylor KM, Gee JMW. Experimental endocrine resistance: concepts and strategies. In: Therapeutic resistance to anti-hormonal drugs in breast cancer: new molecular aspects and their potential as targets. Eds: Hiscox S, Gee J and Nicholson RI 2009. Springer Publishing, London, pp1-26.

Hiscox S, Jordan N, Morgan L, Smith C, Goddard L, Gee JMW, Nicholson RI. Adverse features of acquired antihormone resistance and their targeting. In: Therapeutic resistance to anti-hormonal drugs in breast cancer: new molecular aspects and their potential as targets. Eds: Hiscox S, Gee J and Nicholson RI 2009. Springer Publishing, London, pp139-160.

Hutcheson IR, Nicholson RI & Gee JM. MAP Kinase family members and endocrine response and survival in breast cancer. In Commentaries in breast cancer: prognostic and predictive factors in breast cancer. 2nd Edition, eds. Walker RA & Thompson AM 2008. Informa UK Ltd, London, pp122-138.

Nicholson RI, Hutcheson IR, Jones HE, Taylor K, Hiscox SE and Gee JMW (2008, in press).Compensatory signalling promoted by anti-hormones and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted treatments. In Breast Cancer: prognosis, treatment and prevention, Pasqualini, JR (ed). Taylor and Francis.

Hiscox S, Gee JM and Nicholson, RI. (2006). Endocrine resistance and breast cancer invasion, In: Metastasis of Breast Cancer, W Jiang, O Foysted and RE Mansel (eds). pp74-83, Kluwer Publishers.

Hutcheson, I.R., Gee, J.M.W. & Nicholson, R.I. (2003). MAP kinase family members and endocrine response and survival in breast cancer. In Commentaries in breast cancer: prognostic and predictive factors in breast cancer. 1st Edition, Walker, R.A. (ed) pp. 147-167. Martin Dunitz Ltd: London.

Gee, J.M.W. & Nicholson, R.I. (2002). The Breast Cancer Phenotype and Endocrine Response: Implications for New Drug Development Initiatives. In Breast Cancer: Prognosis, Treatment and Prevention, Pasqualini, J.R. (ed) pp. 301-342. Marcel Dekker Inc: New York.

Nicholson, R.I. & Gee, J.M.W. (2002). Future Prospects for the Endocrine Management of Breast Cancer. In Endocrine Therapy of Breast Cancer, Robertson, J.F.R., Nicholson, R.I. & Hayes, D.F. (eds) pp. 265-274. Martin Dunitz Ltd: London.

Nicholson, R.I., Madden, T.A., Bryant, S. & Gee, J.M.W. (2002). Cellular and Molecular Actions of Oestrogens and Anti‑oestrogens in Breast Cancer. In Endocrine Therapy of Breast Cancer, Robertson, J.F.R., Nicholson, R.I. & Hayes, D.F. (eds) pp. 127-154. Martin Dunitz Ltd: London.

Nicholson, R. I., Hutcheson, I. R., Harper, M. E., Knowlden, J. M., Barrow, D., McClelland, R. A., Jones, H. E., Wakeling, A. E. and Gee, J. M. (2002). Modulation of EGFR in endocrine-resistant, oestrogen receptor-positive breast cancer. In:
L. Castagnetta, B. Agostara, L. Massimo, G. Maontalto, and H. Leon Bradlow (eds.), Hormone related tumours: novel approaches to prevention and treatment, Vol. 963, pp.104-116. New York: Annals of the New York Academy of Sciences.

Willsher, P.C., Kenny, F.S., Gee, J.M.W., Nicholson, R.I. & Robertson, J.F.R. (2002). Biological changes in primary breast cancer during anti‑oestrogen therapies. In Endocrine Therapy in Breast Cancer, Robertson, J.F.R., Nicholson, R.I. & Hayes, D.F. (eds) pp. 209-232. Martin Dunitz Ltd: London.

Online Journals since 2001

Jones, H.E., Gee, J.M.W., Hutcheson, I.R. & Nicholson, R.I. (2006). Growth factor pathway switching: implications for the use of gefitinib and trastuzumab. Breast Cancer Online.

Gee, J.M., Giles, M.G. & Nicholson, R.I. (2004). Extreme growth factor signalling can promote oestrogen receptor-alpha loss: therapeutic implications in breast cancer. Breast Cancer Res, 6, 162-3.

Nicholson, R.I., Giles, M.G., Hutcheson, I.R., Madden, T.A. &Gee, J.M.W. (2004). Impact of altered growth factor signalling on endocrine response in breast cancer and the transition from ER+ to ER- disease. Breast Cancer Online.

Nicholson RI, Jones HE, Gee JMW (2004). EGFR inhibitors in breast cancer. Signal.

Gee, J.M. & Knowlden, J.M. (2003). ADAM metalloproteases and EGFR signalling. Breast Cancer Res, 5, 223-4.

Gee, J.M. & Nicholson, R.I. (2003). Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization. Breast Cancer Res, 5, 126-9.

Nicholson, R.I., Wakeling, A.E. & Gee, J.M.W. (2003). Prospects for combining hormonal and anti-EGFR inhibition. Breast Cancer Online, 6

Gee, J.M.W. (2002). Chaperone-mediated destruction of erbB2: relevance to tyrosine kinase inhibitors. Breast Cancer Research, 4, 205-206.

Patents

LIV1 gene (with RI Nicholson);

Zinc transporter family/predictive biomarkers in breast tumours (Kathryn Taylor with RI Nicholson & J Gee)

Abstracts and Conference Proceedings

Selected peer-reviewed abstracts since 2001

Gee JMW, Lewis LJ, Farrow L, McClelland RA, Nicholson RI. Anti-hormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance, 1st International Symposium of Journal of Hormone Molecular Biology and Clinical Investigation Sept 2010 (in press).

Gee JM, Aleskandarany MA, Finlay P, Farrow L, Nicholson RI, Habashy HO, Green AR, Rakha EA, Powe DG, Jasani B, Barrett-Lee PJ, Robertson JF, Shaw VE, Ellis IO. Immunohistochemical markers progesterone receptor, HER2, Ki67 and bcl-2-associated athanogene 1 and prediction of adjuvant tamoxifen treatment outcome in ER+ early breast cancer. San Antonio Breast Cancer Conference (Breast Cancer Res Treat) Dec 2010 (in press)

Gee JM, Nicholson RI, Habashy HO, Finlay P, Farrow L, Jasani B, Barrett-Lee PJ, Robertson JF, Ellis IO. Transferrin receptor (CD71) identifies poor response to tamoxifen in breast cancer patients. San Antonio Breast Cancer Conference (Breast Cancer Res Treat) Dec 2010 (in press)

Agrawal, A., Robertson, J.F.R., Gutteridge, E., Cheung, K.L., Ellis, I.O., Nicholson, R.I., Gee, J.M.W. Long-term effect of fulvestrant on hormone receptors and proliferation marker in breast cancer. EJC 2010 Supplement 8 (3), 111

Robertson, J.F.R., Dixon, J.M., Sibbering, D.M., Jahan, A., Ellis, I.O.. Channon, E., Nicholson, R.I. and Gee, J.M.W. Biological activity of a combination of fulvestrant 500 mg (F500) plus anastrozole versus F500 alone or anastrozole alone as neoadjuvant treatment for breast cancer. EJC 2010 Supplement 8 (3). 63.

Elsheikh, S.E., Green, A.R., McClelland, R.A., Hutcheson, I.R., Gee, J.M., Nicholson, R.I., and Ellis, I.O. Altered Histone Modifications and Their Regulating Enzymes in Fulvestrant Resistant Breast Cancer Cell Line In Vitro. Modern Pathology 2009, 22, 162.

Hiscox, S., Jordan, N., Crandon-Lewis, A., Jiang, W., Nicholson, R.I., and Gee, J. Overexpression of L1CAM accompanies acquired endocrine resistance and is associated with the development of an aggressive cell phenotype. Cancer Research 2009 69, 213S.

Kuter, I., Anderson, E., Emeribe, U., Finlay, F., Nicholson, R.I., and Gee, J. Comparison of Methods for Detection of Fulvestrant-Induced Changes in Breast Tumor Estrogen and Progesterone Receptor Expression in a Neoadjuvant Trial (NEWEST). Cancer Research 2009 69, 566S-567S.

Kuter, E. Anderson, U. Emeribe, P. Finlay, R. Nicholson, and J. Gee. Comparison of methods for detection of fulvestrant-induced changes in breast tumor estrogen and progesterone receptor expression in a neoadjuvant trial (NEWEST) JCO 2009 27 (15), e11602

O'Brien, C.S., Howell, S.J., Gee, J., Lykkesfeldt, A.E., Nicholson, R.I., and Clarke, R.B. Tamoxifen Resistance in Estrogen Receptor Positive (ER plus ) Breast Cancer Is Driven by Estrogen Receptor Negative (ER-) Cancer Stem-Like Cells. Cancer Research 2009 69, 807S.

Robertson, J.F.R., Dixon, J.M., Sibbering, D.M., Jahan, A., Ellis, I.O., Channon, E.J., Nicholson, R.I., and Gee, J.M.W. Tumor Biomarker Changes Following Pre-Surgical Treatment with 500 mg Fulvestrant Plus Anastrozole Versus 500 mg Fulvestrant Alone and 1 mg Anastrozole Alone. Cancer Research 2009 69, 491S.

Shou, J., Osborne, K.C., Gee, J.M., Nicholson, R.I., and Schiff, R. Akt-dependent phosphorylation on AIB1 serine 967 contributes to breast cancer tamoxifen resistance. Cancer Research 1009 69, 211S.

Bensmail A, Hutcheson I, Giles M, Gee J, Nicholson R. Loss of oestrogen receptor alpha in long-term antioestrogen-resistant cells: reversal by a c-src inhibitor. Breast Cancer Res 2008 10(Suppl 2):O3

Hiscox, S., Goddard, L., Jordan, N., Smith, C., Harper, M., Nicholson, R.I., and Gee, J. Overexpression of CD44 in acquired tamoxifen-resistant breast cancer cells augments their migratory response to heregulin beta 1. Breast Cancer Research 2008 10, P34.

Robertson, J.F.R., Semiglazov, V., Nemsadze, G., Dzagnidze, G., Janjalia, M., Nicholson, R.I., Gee, J.M.W., Armstrong, J., and Study, I. Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer. Breast Cancer Research and Treatment 2008 109, 587-588

Stone, A., Jones, H., Giles, M., Gee, J., and Nicholson, R. Anti-oestrogen therapy switches off tumour suppressors and proapoptotic genes in breast cancer and reveals a new therapeutic opportunity. Breast Cancer Research 2008 10, P41.

Taylor, K.M., Jordan, N., Hiscox, S., Gee, J.M., and Nicholson, R.I. (2008). Zinc transporter HKE4 as a new target in antihormone resistance of breast cancer. Breast Cancer Research 2008 10, P42.

Borley, A.C., Barrett-Lee, P.J., Gee, J.M.W., Show, V.E., Nicholson, R.I., and Hiscox, S.E. Anti-estrogens promote an invasive phenotype in intercellular adhesion deficient breast cancer cells. Breast Cancer Research and Treatment 2007 106, S7-S8

Hill N, Gee JMW, Quirk P, Sharma-Oates A, Nicholson RI, Thomas G, Leonard R, Wagstaff J & Lewis P (2007). Superstes: cancer survival query tool. Eur J Cancer 2003, Suppl 1.

Burmi, R.S., McClelland, R.A., Barrow, D., Ellis, I.O., Robertson, J.F.R., Nicholson, R.I. & Gee, J.M.W. (2006). Microarray studies reveal novel genes associated with endocrine resistance in breast cancer Breast Cancer Res, 8, S11.

Shaw, V.E., Gee, J.M.W., McClelland, R.A., Morgan, H., Rushmere, N. & Nicholson, R.I. (2005). Identification of anti-hormone induced genes as potential therapeutic targets in breast cancer. Proc Amer Assoc Cancer Res, 46, Abstract 3706.

Staka, C.M., Gee, J.M.W. & Nicholson, R.I. (2005). Potential of growth factor signalling kinases/ERalpha crosstalk to undermine the effects of oestrogen deprivation in vitro. Proc Amer Assoc Cancer Res, 46, Abstract 3668.

Gee, J., Shaw, V., Burmi, R., McClelland, R., Morgan, H., Harper, M., Hiscox, S., Barrow, D., Lewis, P. & Nicholson, R. (2004). Array profiling of survival and resistance genes in anti-hormone-treated breast cancer cells. Intl J Mol Med, 14, S81.

Gee, J.M.W., Gutteridge, E., Robertson, J.F., Wakeling, A.E., Jones, H.E. & Nicholson, R.I. (2004). Biological markers during early treatment of tamoxifen-resistant breast cancer with gefitinib (‘Iressa’). Breast Cancer Res Treat, 88, S216.

Gutteridge, E., Gee, J.M.W., Nicholson, R.I. & Robertson, J.F.R. (2004). Biological markers associated with response to gefitinib (‘Iressa’) in patients with breast cancer. Proc Am Soc Clin Oncol, 23, Abstract 38.

Gee, J.M.W., Rubini, M., Robertson, J.F., Ellis, I.O., Gutteridge, E. & Nicholson, R.I. (2003). Type 1 insulin-like growth factor receptor expression and activation in clinical breast cancer. Breast Cancer Res Treat, 82, S102.

Boyns, F., Gee, J.M.W. & Nicholson, R.I. (2003). Tamoxifen agonism and EGFR signalling in tamoxifen-resistant breast cancer. Eur J Biochem, 270 Suppl 1, A503.

Robertson, J.F.R., Gutteridge, E., Cheung, K.L., Owers, R., Koehler, M., Hamilton, L., Gee, J.M.W. & Nicholson, R.I. (2003). Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study. Proc Am Soc Clin Oncol 22, Abstract 7.

Staka, C.M., Gee, J.M.W. & Nicholson, R.I. (2003). Mechanisms of resistance to oestrogen deprivation in breast cancer. Eur J Biochem, 270 (S1), Abstract 535.

Gee, J.M.W., Harper, M.E., Hutcheson, I.R., Madden, T.A., Barrow, D., Knowlden, J.M., McClelland, R.A., Jordan, N., Wakeling, A.E., Nicholson, R.I. (2002). ZD1839 ('Iressa') improves the antitumour activity of ICI 182, 780 ('Faslodex') in anti-hormone responsive breast cancer. Eur J Cancer, 38, Abstract 185.

Gee, J.M.W., Hutcheson, I.R., Knowlden, J.M., Barrow, D., Harper, M.E., Wakeling, A.E. & Nicholson, R.I. (2001). The EGFR-Selective Tyrosine Kinase Inhibitor ZD1839 ('Iressa') is an Effective Inhibitor of Tamoxifen-Resistant Breast Cancer Growth. ASCO Proceedings San Francisco, Abstract 282 (also Eur J Cancer, 37 Suppl 6, S261 & Proc Am Soc Clin Oncol, 20, 71A).